Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Seribantumab + XL147 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Seribantumab | MM-121|SAR256212 | HER3 (ERBB3) Antibody 23 | Seribantumab (SAR256212) is a human monoclonal antibody that binds ERBB3 (HER3) and prevents ligand binding and heterodimerization with other ERBB family members, resulting in decreased activation of downstream signaling and potentially leading to reduced tumor growth (PMID: 26310543, PMID: 30975923). | |
XL147 | SAR245408|Pilaralisib|XL-147 | PI3K Inhibitor (Pan) 42 | Pilaralisib (XL147) is an inhibitor of all class I PI3Ks, thereby blocking activation of the PI3K signaling pathway and potentially resulting in antitumor activity including inhibition of cell proliferation, cell invasion, and tumor growth (PMID: 25637314, PMID: 29593099). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|